We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Toxins & Toxoids of Clostridium Difficile Ribotypes 027 and 078
Product News

Toxins & Toxoids of Clostridium Difficile Ribotypes 027 and 078

Toxins & Toxoids of Clostridium Difficile Ribotypes 027 and 078
Product News

Toxins & Toxoids of Clostridium Difficile Ribotypes 027 and 078


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Toxins & Toxoids of Clostridium Difficile Ribotypes 027 and 078"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Native Antigen Company (NAC) has announced the release of highly purified toxins and toxoids of Clostridium difficile ribotypes 027 and 078 for use in research, vaccine development and by IVD manufacturers.

Clostridium difficile infection (CDI) is a major cause of morbidity and mortality in economically developed countries. CDI is primarily linked with hospital admission and prior antimicrobial treatment.

Although significant advances have been made to reduce incidence, a number of hypervirulent and highly transmissible strains have recently emerged.

Resultant healthcare challenges are compounded as widespread use of antibiotics encourages both the emergence of resistant strains and reoccurrence of infection, especially in the elderly.

The availability of these cost effective, high performance toxins and toxoids is timely and supports the increasing healthcare focus on combating these hypervirulent strains.

To satisfy a broad range of applications, the products are offered as separate preparations in a variety of vial sizes and are suitable for long term storage.

Advertisement